Sign In
Buy HIMS
$32.16
+1.34 (+4.35%)
At Close: Aug 04, 2026
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
03:00pm, Wednesday, 02'nd Apr 2025
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
07:44pm, Tuesday, 01'st Apr 2025
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
Why Hims & Hers Health Stock Soared Tuesday
04:15pm, Tuesday, 01'st Apr 2025
Shares of Hims & Hers Health (HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more
Hims & Hers shares rise as company adds new weight-loss medications to platform
03:21pm, Tuesday, 01'st Apr 2025
Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have e
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
02:30pm, Tuesday, 01'st Apr 2025
Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli L
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
01:39pm, Tuesday, 01'st Apr 2025
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Monday, 31'st Mar 2025
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $29.55, representing a +1.41% change from its previous close.
Is Hims & Hers Stock Too Cheap to Pass Up?
08:15am, Saturday, 29'th Mar 2025
Hims & Hers (HIMS -8.84%) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today.
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
04:55am, Friday, 28'th Mar 2025
What goes up can come down. Investors who jumped on the Hims & Hers Health (HIMS -4.12%) bandwagon have experienced this pain first-hand.
Here's why Hims & Hers stock price has crashed: buy the dip?
04:13am, Thursday, 27'th Mar 2025
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from i
Hims & Hers Health: Reaching Escape Velocity Goes Unnoticed By The Market
09:15am, Wednesday, 26'th Mar 2025
I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stoc
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
06:50pm, Tuesday, 25'th Mar 2025
Hims & Hers Health, Inc. (HIMS) reachead $37.04 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Tuesday, 25'th Mar 2025
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
06:11am, Tuesday, 25'th Mar 2025
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and wome
Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?
09:05am, Monday, 24'th Mar 2025
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
